OOCENTA

Allergan Sales, LLC

Application Filed: 2017-02-14
Trademark Application Details
Trademark Logo OOCENTA
733
Live/Pending
FOURTH EXTENSION - GRANTED
Research OneLook Acronym Finder
Serial Number87335700
Mark Drawing Code4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Law Office AssignedL20
Employee NameCLARKE, NANCY L

Timeline

2017-02-14Application Filed
2017-05-30Published for Opposition
2017-07-25Location: INTENT TO USE SECTION
2019-06-14Status: Live/Pending
2019-06-18Transaction Date

Trademark Applicants & Owners

Owner: Allergan Sales, LLC
Address2525 Dupont Drive Irvine DE 92612
Legal Entity TypeLimited Liability Company
Legal Entity StateDE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

SUSAN J. HINCHEY
ALLERGAN, INC.
2525 DUPONT DRIVE
IRVINE, CA 92612

Good, Services, and Codes

International Codes:5
U.S. Codes:006,018,044,046,051,052
Type CodeType
GS0051Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Filing History

DescriptionDateEvent Coding
NEW APPLICATION ENTERED IN TRAM2017-02-171 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2017-02-212 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER2017-03-113 DOCK D:Assigned to Examiner
SUSPENSION LETTER WRITTEN2017-03-204 CNSL R:Renewal
LETTER OF SUSPENSION E-MAILED2017-03-205 GNSL F:First Action
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED2017-03-206 GNS3 O:Outgoing Correspondence
EXAMINERS AMENDMENT -WRITTEN2017-03-227 CNEA R:Renewal
EXAMINERS AMENDMENT E-MAILED2017-03-228 GNEA O:Outgoing Correspondence
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED2017-03-229 GNEN O:Outgoing Correspondence
EXAMINER'S AMENDMENT ENTERED2017-03-2210 XAEC I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER2017-03-2211 CNSA P:
ASSIGNED TO LIE2017-04-2412 ALIE A:Allowance for Publication
LAW OFFICE PUBLICATION REVIEW COMPLETED2017-04-2613 PREV O:Outgoing Correspondence
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2017-05-1014 NONP E:E-Mail
PUBLISHED FOR OPPOSITION2017-05-3015 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2017-05-3016 NPUB E:E-Mail
NOA E-MAILED - SOU REQUIRED FROM APPLICANT2017-07-2517 NOAM E:E-Mail
TEAS EXTENSION RECEIVED2017-12-0818 EEXT I:Incoming Correspondence
EXTENSION 1 FILED2017-12-0819 EXT1 S:
EXTENSION 1 GRANTED2017-12-0820 EX1G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2017-12-1221 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2018-07-1622 EEXT I:Incoming Correspondence
EXTENSION 2 FILED2018-07-1623 EXT2 S:
EXTENSION 2 GRANTED2018-07-1624 EX2G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2018-07-1825 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2019-01-1026 EEXT I:Incoming Correspondence
EXTENSION 3 FILED2019-01-1027 EXT3 S:
EXTENSION 3 GRANTED2019-01-1028 EX3G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2019-01-1229 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2019-06-1430 EEXT I:Incoming Correspondence
EXTENSION 4 FILED2019-06-1431 EXT4 S:
EXTENSION 4 GRANTED2019-06-1432 EX4G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2019-06-1833 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2020-01-1434 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL2020-01-1635 AITU A:Allowance for Publication
EXTENSION 5 FILED2020-01-1436 EXT5 S:
EXTENSION 5 GRANTED2020-01-1637 EX5G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2020-01-1738 EXRA E:E-Mail
ABANDONMENT - NO USE STATEMENT FILED2020-08-3139 ABN6 S:
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED2020-08-3140 MAB6 E:E-Mail

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed